In order to elucidate the pathogenesis and explore potential diagnostic and immunotherapeutic pathways, this study was conducted to investigate if there are differences in the effect of the IL-23/IL-17 axis in two chronic liver diseases with different etiopathogenesis—CHC and NASH. Here, IL23A is linked to metabolic dysfunction-associated steatohepatitis.